Patients' preference for subsequent therapy following secondary failure of metformin and sulphonylurea

Practical Diabetes International

Volumn 26, Issue 7, 2009, Pages 282-284

  Khan, Hamida ^a   Coyle, Frances M ^a   Chowdhury, Tahseen A ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Insulin; Oral hypoglycaemic therapy; Secondary failure

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; ASIAN; BODY MASS; CAUCASIAN; CONTROLLED STUDY; DISEASE DURATION; DRUG PREFERENCE; DRUG TREATMENT FAILURE; ETHNIC DIFFERENCE; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT DECISION MAKING; PHYSICIAN ATTITUDE; UNITED KINGDOM;

EID: 70450210256     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1400     Document Type: Article

References (8)

1. UK Prospective Diabetes Study Group. UKPDS 16: Overview of six years' therapy of type 2 diabetes: a progressive disease. Diabetes 2005; 44: 1249-1258.
2. JBS 2: Joint British Societies Guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl 5): v1-v52.
3. NICE. Type 2 diabetes: National Clinical Guideline for management in primary and secondary care (update). www.nice.org.uk/nice media/pdf/ CG66diabetesfullguide line.pdf [accessed 17.11.08].
4. Halperin F, Ingelfinger JR, McMahon GT. Management of type 2 diabetes - polling results. N Engl J Med 2008; 358: e8-e10. (Pubitemid 351240756)
5. Goldberg RB, Holman R, Drucker DJ. Management of type 2 diabetes. N Engl J Med 2008: 358: 293-297.
6. Khan H, Lasker SS, Chowdhury TA. Prevalence and reasons for insulin refusal amongst Bangladeshi patients with poorly controlled type 2 diabetes in East London. Diabet Med 2008; 25: 1108-1111.
7. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. (Pubitemid 46919772)